ТИСДЕЙЛ Майкл Джон (GB),ИЛЕЙ Хелен Лаура (GB),РАССЕЛ Стив Томас (GB),МИЛЛЕР Кевин Берк (US)
申请号：
RU2010126171/15
公开号：
RU2010126171A
申请日:
2008.10.03
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. The composition of at least one double-stranded RNA (PKR) protein kinase inhibitor to enhance treatment. ! 2. The composition according to claim 1, wherein said at least one double-stranded RNA dependent protein kinase (PKR) inhibitor is a phosphorylation inhibitor. ! 3. The composition of claim 1, wherein said enhancement is an enhancement of said treatment. ! 4. The composition according to claim 1, where the specified gain is a decrease in the frequency and / or severity of at least one side effect of the specified treatment. ! 5. The composition according to claim 1, where the specified inhibitor is intended for enteral or parenteral administration. ! 6. The composition according to claim 1, where the specified inhibitor is a food composition. ! 7. The composition according to claim 1, where the specified inhibitor is an inhibitor of cell growth. ! 8. The composition according to claim 1, where the specified inhibitor is an inhibitor of cell replication. !9. The composition of claim 1, further comprising at least one protein phosphatase 1 alpha modifier (PP1a). ! 10. The composition of claim 9, wherein said PP1a dephosphorylates phosphorylated PKR. ! 11. The composition of claim 9, wherein said PP1a modifier is a branched chain amino acid. ! 12. The composition of claim 9, wherein said PP1a modifier is leucine. ! 13. The composition of claim 9, wherein said PP1a modifier is at least one nutrient. ! 14. The composition according to claim 1, additionally containing an agent for improving the delivery of a therapeutic agent to metabolically active tissue. ! 15. The composition of claim 14, wherein said agent is at least one of arginine and citrulline. ! 16. The composition according to claim 1, additionally containing1. Композиция по меньшей мере одного ингибитора протеинкиназы, зависимой от двухцепочечной РНК (PKR), для усиления лечения. ! 2. Композиция по п.1, в которой указанный по меньшей мере один ингибитор протеинкиназы, зависимой от двухцепочечной РНК (P
